MAPT and Alzheimer disease: Epigenetic drugs (Tables S3 and S6), which target modifications that regulate gene expression without altering the DNA sequence, modify the epigenetic landscape that contributes to the pathogenesis of AD, including the expression of genes involved in amyloid-beta (Aβ) production, tau hyperphosphorylation, neuroinflammation, and synaptic function [188,189].